{"SPADE_N_14472": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14472", "Peptide Name": "LL-10+ (Synthetic AMPs, LL-37 derived,, XXA, UCLL1c; BBMm)", "Source": "amino acid truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative", "Family": "Not found", "Gene": "Not found", "Sequence": "LWGRFFRKWK", "Sequence Length": 10, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anti-MRSA", "Antibiofilm"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 1423.71, "PI": 12.0, "Hydrophobicity": -0.96, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Mechesso AF, Zhang W, Su Y, Xie J, Wang G. 2024", "Reference": "Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3.PubMed", "Title": "Segment-Based Peptide Design Reveals the Importance of N-Terminal High Cationicity for Antimicrobial Activity Against Gram-Negative Pathogens."}], "Frequent Amino Acids": "FKR", "Absent Amino Acids": "ACDEHIMNOPQSTUVY", "Basic Residues": 4, "Acidic Residues": 0, "Hydrophobic Residues": 5, "Polar Residues": 4, "Positive Residues": 4, "Negative Residues": 0, "Net Charge": 4, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (46.15%) toD2-NH2F=W=K=R: 20%. GRAVY: -0.96, mol Wt: 1423.723; mol formula: C72H104N20O11; mol ex coeff: 11100.Activity: active against  S. aureus USA300 MRSA (MIC 16 uM), S. epidermidis 1457 (MIC 32 uM), P. aeruginosa E411-17 (MIC 16 ug/ml), E. coli E423-17 (MIC 32 uM), and A-baumannii B28-16 (MIC >32 uM).Biofilms: inhibit biofilm formation:bacteria:S. aureus;  inhibited biofilm formation:bacteria:P. aeruginosa; disrupted preformed biofilm:bacteria:S. aureus; disrupted preformed biofilm:bacteria:P. aeruginosa;In vitro toxicity: human RBC: not hemo.lytic till 400 uM. Not toxic to human keratinocyte HaCaT cells (LC50 > 100 uM), human hepatoma HepG2 cells (LC50 >100 uM), and human lung carcinoma A549 cells (LC50 >100 uM).MOA:bacteria:S. aureus USA300: membrane permeation.Animal model:mouse: wound healing model:S. aureus: ~2 logs CFU reduction after treatment once at 10 mg/kg.", "Similar Sequences": [{"SPADE_ID": "SPADE_N_03315", "Similarity": 1.0, "Sequence": "MGWLKKIGKKIERVGQHTRDATIQGLGIAQQAANVAATARGGRATAAVNAAQQAIGLGQITADRTHQGVREIKKGIKKLWG"}, {"SPADE_ID": "SPADE_N_05519", "Similarity": 1.0, "Sequence": "NKGCAICSIGAACLVDGPIPDFEIAGATGLFGLWG"}, {"SPADE_ID": "SPADE_N_06150", "Similarity": 1.0, "Sequence": "MKKAVIVENKGCATCSIGAACLVDGPIPDFEIAGATGLFGLWG"}]}}}